InsidersTradesSigma
Follow the Globus Medical INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Globus Medical INC has logged 73 reports. Market capitalisation: €11.6bn. The latest transaction was disclosed on 19 August 2026 (Levée d'options). Among the most active insiders: Davidar David D. All data is free.
73
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€13m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Globus Medical INC Buy (bullish), based on 13 analysts. Average price target: US$103.23.
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,762 of 29,063 companies
69.1
score / 100
Value57
Quality81
FCF yld5.2%
Earn yld4.8%
EV/EBITDA13.8x
ROE12%
Gross mgn67%
Net mgn18%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 August 2026
Declarations73 total
25,000 shares@ US$53.27Class A Common StockSEC:0001193125-26-357121:0
25,000 shares@ US$87.0386Class A Common StockSEC:0001193125-26-357121:1
25,000 shares@ US$87.040.019% mcap66.3% of flowCommonSEC144:0001974078-26-000312
2,500 shares0Class A Common StockSEC:0001193125-26-321442:0
25,000 shares@ US$26.270.0052% mcap5.9% of flowClass A Common StockSEC:0001193125-26-263997:0
25,000 shares@ US$80.76290.016% mcap18.3% of flowClass A Common StockSEC:0001193125-26-263997:1
25,000 shares@ US$81.000.018% mcap14.8% of flowCommonSEC144:0001974078-26-000224
20,000 shares@ US$43.5838.2% of flowClass A Common StockSEC:0001193125-26-083348:0
10,000 shares@ US$45.6419.8% of flowClass A Common StockSEC:0001193125-26-055137:0
3,594 shares@ US$51.8748.9% of flowClass A Common StockSEC:0001193125-26-010699:0
2,000 shares@ US$101.1016.6% of flowClass A Common StockSEC:0001193125-26-010697:0
6,100 shares0Class A Common StockSEC:0001193125-26-002966:0
4,000 shares@ US$88.8534.7% of flowClass A Common StockSEC:0001193125-25-320898:0
34,375 shares@ US$25.5255.8% of flowClass A Common StockSEC:0001193125-25-314329:0
3,646 shares@ US$53.14100.0% of flowClass A Common StockSEC:0001193125-25-307215:0
7,500 shares@ US$25.9620.8% of flowClass A Common StockSEC:0001193125-25-302649:0
25,000 shares@ US$25.525.5% of flowClass A Common StockSEC:0001193125-25-280500:0
25,000 shares@ US$44.14100.0% of flowClass A Common StockSEC:0001193125-25-280472:0
8,000 shares@ US$81.0027.5% of flowClass A Common StockSEC:0001193125-25-274288:0
10,000 shares@ US$58.4633.6% of flowClass A Common StockSEC:0001193125-25-205135:0
7,500 shares@ US$78.6857.9% of flowClass A Common StockSEC:0000950170-25-032220:0
5,833 shares@ US$49.6510.1% of flowClass A Common StockSEC:0000950170-25-005353:0
2,500 shares@ US$24.218.9% of flowClass A Common StockSEC:0000950170-24-133260:0
13,278 shares@ US$65.0546.9% of flowClass A Common StockSEC:0000950170-24-130597:0
50,000 shares@ US$43.7741.9% of flowClass A Common StockSEC:0000950170-24-130588:0
25 of 73 declarations
关于 Globus Medical INC
Globus Medical Inc. (NYSE: GMED) 是一家在美国纽约证券交易所上市的医疗技术公司，总部位于美国宾夕法尼亚州奥杜邦。该公司成立于 2003 年，业务围绕肌肉骨骼解决方案展开，在脊柱领域拥有尤其强大的特许经营权，并在骨科创伤、关节置换、再生生物材料和辅助技术方面拥有更广泛的业务。其模式结合了产品设计、制造、商业化和临床支持，为其提供了一个垂直整合的平台，旨在为外科医生和医院提供基于手术的解决方案，而非孤立的产品。([investors.globusmedical.com](https://investors.globusmedical.com/?utm_source=openai)) 从股票分析师的角度来看，GMED 定位在一个结构性有吸引力的市场。需求受到人口老龄化、脊柱疾病的普遍性以及向更高效、微创手术持续转变的支持。Globus 通过持续的创新文化、广泛的手术产品组合以及旨在与外科医生和护理团队保持密切关系的高接触商业模式来区分自己。该公司将自己描述为一个单一的运营平台，这有助于围绕未满足的临床需求协调研究、开发、制造、教育和销售。([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000156276225000026/gmed-20241231x10k.htm?utm_source=openai)) 该公司的根基在于脊柱领域，最初在此建立了品牌和技术信誉，随后扩展到邻近的肌肉骨骼类别。近年来，通过重大交易，其战略格局变得更具雄心，最显著的是 NuVasive 收购以及 2025 年 Nevro 收购的完成。管理层强调，整合仍然是核心运营重点，同时还有强大的新产品线和对商业执行的持续投资。([investors.globusmedical.com](https://investors.globusmedical.com/news-events/press-releases?utm_source=openai)) 从地理上看，Globus 的大部分业务来自美国，同时通过分销商和非美国商业渠道保持国际业务。最近的披露表明其势头强劲：该公司报告 2025 年全年销售额为 $2.9389 billion，增长 16.7%，第四季度增长由核心脊柱特许经营权和辅助技术推动。在 2026 年初，管理层重申其在整合收购过程中，将重点放在高于市场增长、产品创新和严谨执行上。([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/gmed-ye2025ex991.htm?utm_source=openai)) 总的来说，Globus Medical 可以被视为一家以增长为导向的医疗保健技术公司，拥有重要的美国脊柱特许经营权、不断扩大的手术范围以及以创新、规模和收购整合为中心的战略。([investors.globusmedical.com](https://www.investors.globusmedical.com/news-events/press-releases?utm_source=openai))
